Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms (Q38699858)

5 September 2017

title

Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms (English)

1 reference

5 September 2017

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26776915%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Inês-de-Paula Monteiro

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26776915%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Giannis Mountzios

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26776915%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Ramon Andrade de Mello

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26776915%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

18 January 2016

1 reference

5 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26776915%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26776915%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26776915%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

551-564

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26776915%20AND%20SRC:MED&resulttype=core&format=json

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Lung cancer: potential targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

The journey from discoveries in fundamental immunology to cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

New strategies in lung cancer: translating immunotherapy into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Immunotherapy and lung cancer: current developments and novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.15.309

21 January 2018

Identifiers

DOI

10.2217/FON.15.309

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26776915%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference